Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Dr. Simon Pimstone will participate in key virtual investor conferences.

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Dr. Simon Pimstone will participate in key virtual investor conferences. These include:

• Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on November 16, 2020.
• Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET.
• Jefferies Virtual London Healthcare Conference on November 19, 2020, at 9:40 am ET (2:40 pm GMT).

Details and webcasts will be available on the company website following the events.

Argus Session date unavailable

+3.46% session move Open Argus

Details

News Market Reaction – XENE

The recorded move for XENE in the trading session of this news was +3.46%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:

• Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on Monday, November 16, 2020
• Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 pm ET
• Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 9:40 am ET (2:40 pm GMT)
  

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the upcoming virtual conferences for Xenon Pharmaceuticals in November 2020?

Xenon Pharmaceuticals will participate in several virtual investor conferences in November 2020, including Guggenheim Healthcare Neuro/Immunology Day on November 16, Stifel 2020 Healthcare Conference on November 17 at 4:40 pm ET, and Jefferies London Healthcare Conference on November 19 at 9:40 am ET.

Who is the CEO of Xenon Pharmaceuticals participating in the investor conferences?

The CEO of Xenon Pharmaceuticals is Dr. Simon Pimstone, who will represent the company at the upcoming virtual investor conferences.

Where can I find more information about Xenon Pharmaceuticals' conference presentations?

More information about Xenon Pharmaceuticals' conference presentations can be found in the 'Investors' section of their website at www.xenon-pharma.com.

Will there be webcasts available for the Xenon Pharmaceuticals conferences?

Yes, webcasts of the presentations will be made available for replay on the Xenon Pharmaceuticals website for 30 days following each event.

What is Xenon Pharmaceuticals' focus in the biopharmaceutical industry?

Xenon Pharmaceuticals is focused on developing innovative therapeutics for neurological disorders, particularly in areas of high unmet need, such as epilepsy.